Tech Company Financing Transactions
AgeX Therapeutics Funding Round
AgeX Therapeutics closed a $10 million funding round on 8/18/2017. Investors included private investors.
Transaction Overview
Company Name
Announced On
8/18/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1010 Atlantic Ave. 102
Alameda, CA 94501
USA
Alameda, CA 94501
USA
Phone
Website
Email Address
Overview
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael West
Chief Financial Officer
Russell Skibsted
Chief Information Officer
Ivan Labat
Chief Operating Officer
Nafees Malik
VP - Engineering
Aubrey de Grey
VP - General Counsel
Judith Segall
VP - R & D
Dana Larocca
VP - R & D
Hal Sternberg
Browse more venture capital transactions:
Prev: 8/18/2017: Union Station venture capital transaction
Next: 8/18/2017: Atreca venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs